Hims & Hers Health (HIMS) is up sharply as investors react to fresh momentum around peptides after the FDA updated its 503A bulk drug substance categories, removing 12 peptides from Category 2 effective April 22, 2026. The change is being treated as a de-risking signal for parts of the peptide ecosystem and is lifting expectations that Hims & Hers could eventually offer peptide-related treatments under tighter medical oversight rather than leaving demand to gray-market channels. (fda.gov)

The market focus is on “optionality”: Hims & Hers already operates a large direct-to-consumer telehealth platform and has been building more verticalized medication capabilities, so any regulatory thaw that broadens the addressable set of personalized therapies can be meaningful to the long-term growth narrative. While removal from Category 2 is not the same as full approval for compounding, traders are treating it as a step toward clearer pathways and future PCAC review processes. (fda.gov)

The peptide excitement is landing as Hims & Hers continues a high-profile transition in weight-loss: the company moved away from the most contentious aspects of compounded GLP-1 offerings after a legal dispute and strategic reset with Novo Nordisk, which removed a major overhang but also reshaped near-term economics. Against that backdrop, investors appear to be looking for the next scalable category that can complement branded GLP-1 distribution and the core subscription engine. (pharmaceutical-technology.com)

Key swing factors include whether regulators provide further clarity on compounding pathways for peptides beyond the Category 2 change, any product launches or clinical/medical positioning announcements from Hims & Hers tied to peptide protocols, and upcoming execution milestones such as integration planning for its agreed acquisition of Eucalyptus (expected to close mid-2026). The next earnings cycle is also a near-term catalyst for updated 2026 outlook commentary and unit economics after the GLP-1 pivot. (investors.hims.com)